Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED Director's Dealing 2016

Apr 10, 2016

65387_rns_2016-04-10_06daaf73-ed08-48d6-9bd7-205397b67c9e.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Medical Developments International Limited ABN 14 106 340 667

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director David Williams
Date of last notice 1 March 2016

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Lawn Views Pty Ltd – Indirect
Moggs Creek Pty Ltd – Indirect
Mr. David Williams (Trustee) - Indirect
Kidder Peabody Pty Ltd – Indirect
Ward Williams – Indirect
Saul Williams – Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Lawn Views Pty Ltd – 7,834,119
Moggs Creek Pty Ltd – 8,043,912
Mr. David Williams (Trustee) – 822,000
Kidder Peabody Pty Ltd – 1,000,000
Ward Williams – 23,446
Saul Williams – 8,513
Date of change 8 April 2016
No. of securities held prior to change 17,731,990
Class Fully Paid Ordinary Shares
Number acquired 77,865
Number disposed Nil
  • See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration 77,865 shares @ $4.56 via participation in

Note: If consideration is non-cash, provide details and estimated valuation the Dividend Reinvestment Plan

No. of securities held after change 17,809,855 Nature of change Issue of shares via participation in the

Example: on-market trade, off-market trade, exercise of options, MVP Dividend Reinvestment Plan issue of securities under dividend reinvestment plan, participation in

buy-back announced on 18 February 2016.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 319] intentionally omitted <==

----- Start of picture text -----

Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above No traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to N/A proceed during this period? If prior written clearance was provided, on what date was this N/A provided?

  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Medical Developments International Limited ABN 14 106 340 667

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Mr. Robert Maxwell Johnston

Date of last notice 31 October 2013

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
JONDOL PTY LTD – Superannuation
Fund
Date of change 8 April 2016
No. of securities held prior to change 30,000
Class Fully Paid Ordinary Shares
Number acquired 131
Number disposed Nil
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
131 shares @ $4.56 via participation in the
Dividend Reinvestment Plan
No. of securities held after change 30,131
  • See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Issue of shares via participation in the Example: on-market trade, off-market trade, exercise of options, MVP Dividend Reinvestment Plan issue of securities under dividend reinvestment plan, participation in buy-back announced on 18 February 2016.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 319] intentionally omitted <==

----- Start of picture text -----

Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?

  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Medical Developments International Limited ABN 14 106 340 667

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Allan McCallum
Date of last notice 30 September 2015

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Mullacam Pty Ltd – 329,235
McCallum Family Super fund – 50,787
Date of change 8 April 2016
No. of securities held prior to change 380,022
Class Fully Paid Ordinary Shares
Number acquired 1,668
Number disposed Nil
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
1,668 shares @ $4.56 via participation in
the Dividend Reinvestment Plan
No. of securities held after change 381,690
  • See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Issue of shares via participation in the Example: on-market trade, off-market trade, exercise of options, MVP Dividend Reinvestment Plan issue of securities under dividend reinvestment plan, participation in buy-back announced on 18 February 2016.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 319] intentionally omitted <==

----- Start of picture text -----

Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?

  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Medical Developments International Limited ABN 14 106 340 667

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Harry Oxer

Date of last notice 11 October 2013

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Dr. Harry Frank Oxer
Date of change 8 April 2016
No. of securities held prior to change 207,013
Class Fully Paid Ordinary Shares
Number acquired 909
Number disposed Nil
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
909 shares @ $4.56 via participation in the
Dividend Reinvestment Plan
No. of securities held after change 207,922
  • See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Issue of shares via participation in the Example: on-market trade, off-market trade, exercise of options, MVP Dividend Reinvestment Plan issue of securities under dividend reinvestment plan, participation in buy-back announced on 18 February 2016.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 319] intentionally omitted <==

----- Start of picture text -----

Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?

  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Medical Developments International Limited ABN 14 106 340 667

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Mr. Philip Powell

Date of last notice 30 September 2015

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
PNSF Pty Ltd as trustee for the Prime
Numbers Superannuation Fund
Date of change 8 April 2016
No. of securities held prior to change 252,074
Class Fully Paid Ordinary Shares
Number acquired 1,106
Number disposed Nil
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
1,106 shares @ $4.56 via participation in
the Dividend Reinvestment Plan
No. of securities held after change 253,180
  • See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Issue of shares via participation in the Example: on-market trade, off-market trade, exercise of options, MVP Dividend Reinvestment Plan issue of securities under dividend reinvestment plan, participation in buy-back announced on 18 February 2016.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 319] intentionally omitted <==

----- Start of picture text -----

Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?

  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Medical Developments International Limited ABN 14 106 340 667

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Leon Hoare
Date of last notice 26 May 2015

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Mr. Leon Hoare
Date of change 8 April 2016
No. of securities held prior to change 10,000
Class Fully Paid Ordinary Shares
Number acquired 43
Number disposed Nil
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
43 shares @ $4.56 via participation in the
Dividend Reinvestment Plan
No. of securities held after change 10,043
  • See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Issue of shares via participation in the Example: on-market trade, off-market trade, exercise of options, MVP Dividend Reinvestment Plan issue of securities under dividend reinvestment plan, participation in buy-back announced on 18 February 2016.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 319] intentionally omitted <==

----- Start of picture text -----

Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change
----- End of picture text -----

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?

  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011